OVERVIEW

We invite you to the first one of the 2021’s Scientific Meetings and Conventions sponsored by the Puerto Rico’s Hematology and Medical Oncology Association (AHOMPR). As the year 2020 came to an end trailing with it the challenges imposed by the COVID-19 pandemic, it also brought with it the need of overcome many of those hurdles with new and improved opportunities to bring the scientific community closer than ever.

The AHOMPR is not an exception, with our first virtual meeting, we bring the opportunity of first-class continuing medical education event for the diagnosis and treatment of patients who pertain to the Hematology and Medical Oncology subspecialty realm.

This Annual Meeting will provide you with the most updated research and with practical information for day to day care of your patients.

This year’s program will bring together world-class and trend setters experts in matters of Hematology and Medical Oncology. You will have the chance to learn from and interact with experts from across the nation and from different continents in areas so diverse such as benign hematology, pediatric hematology and oncology, immunotherapy, biologic and targeted agents. All of it with a multidisciplinary approach in mind. By joining us, you will have the opportunity to learn updated and state-of-the-art care in such broad and exciting areas such as:

- Molecular testing in the new oncologic universe
- New therapeutic tools against oncogene-driven solid tumors
- Novel immunotherapy-based regimens
- The role of consolidation and maintenance immunotherapy
- Integration of surgery, radiation oncology, molecular dissection and immunotherapy in patients with diverse malignancies

We look forward to seeing you there!

Dr. Sixto Perez, M.D.
President AHDMPR
TARGET AUDIENCE

This educational activity is directed toward oncologists and hematologist involved in the treatment of patients with different types of cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other health care professionals interested in the treatment.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of “Academia Médica del Sur” and “(Asociacion de Hematologia y Oncologia Medica de Puerto Rico).”

The “Academia Médica del Sur” is accredited with Commendation by the ACCME to provide continuing medical education for physicians.” The Academia Médica del Sur designates this live webinar presentation for a maximum of (21) AMA, PRA Category 1™ Credits.
Physicians should claim credits commensurate with the extent of their participation in the activity.

For more information:
Germaine Quiñones
Meeting Coordinator
Tel: 787-608-1477
Fax: 787-841-6886
e-Mail: ahomprgq@gmail.com
Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Know the latest developments in the treatment of acute myelogenous leukemia and how to incorporate novel targeted therapies into practice.
- Consider advances in molecular markers to better inform screening, prognosis and treatment decision-making for patients with gastrointestinal cancers.
- Increase knowledge of novel immunotherapies for gastrointestinal cancer, including appropriate patient selection and optimal treatment sequencing.
- Understand the impact COVID-19 has had on breast cancer patients and treatments.
- Incorporate emerging clinical evidence for HER2-targeted agents into individualized treatment plans for patients with early-stage or advanced/metastatic HER2+ breast cancer.
- Analyze recent data on the efficacy and safety of immunotherapy options for the treatment of patients with breast cancer.
- Select appropriate diagnostic approach and treatment in amyloidosis.
- Assess clinical trial data of current and emerging agents and regimens that impact management strategies for patients with Relapsed/Refractory Hodgkin lymphoma (HL).
- Assess clinical data concerning single-agent and combination immunotherapeutic approaches to manage non-metastatic lung cancer.
- Integrate molecular testing strategies to inform treatment selection in patients with oncogene-driven NSCLC.
- Evaluate safety and efficacy data regarding emerging treatment options and novel formulations in the management of MDS and integrate it into clinical scenarios.
- Describe evidence-based strategies for risk stratification and risk-based management of SMM and discuss evolving options to optimize management strategies for patients with high-risk SMM.
- Evaluate current clinical data and emerging approaches with CAR T-cell therapy for the management of patients with hematologic malignancies.
- Discuss criteria for selection of patients for CAR T-cell therapy and best practices for referral and follow-up of patients from community practices.
- Describe the major challenges in the clinical management of patients with cancer brought upon by the COVID-19 pandemic and outline clinical practice recommendations proposed by oncology societies regarding cancer care during the COVID-19 pandemic.
- Recognize guideline recommendations regarding risk stratification, monitoring, and management strategies to mitigate cardiovascular risk in the oncology patient.
- Utilize risk stratification strategies to develop appropriate treatment plans for adult as well as pediatric patients with ALL based on cytogenetic and immunophenotype characteristics.
- Detail strategies for first line and second-line management of patients living with AA and BM failure syndromes, as well as emerging options in the first line setting.
- Recognize and understand molecular features of the five childhood brain tumors that present also in early adulthood and to learn the latest treatments for brain tumors shared by children and young adults.
- Address novel and emerging treatments of pediatric patients with bone and soft tissue sarcoma.
- Explain efficacy and safety data supporting novel therapeutic modalities in SCD.
- Increase knowledge in HSCT and deepen understanding of advanced topics in cellular therapies in pediatric patients.
“OVERCOMING NEW CHALLENGES IN THE ONCOLOGY PRACTICE”

Paul A Meyers, MD
Professor of Pediatrics
Weill Cornell Medical College
Robbins Family Chair in Pediatrics
Vice Chair, Department of Pediatrics
Chief, Sarcoma Service
Memorial Sloan-Kettering Cancer Center
New York, NY 10065

Edgardo S. Santos Castillero, M.D., FACP
Florida Precision Oncology, a Division of Genesis Care
Medical Director of Research Services
Thoracic and Head/Neck Cancer Programs
Clinical Affiliate Associate Professor
Charles E. Schmidt College of Medicine
Florida Atlantic University
Secretary, Florida Society of Clinical Oncology (FLASCO)
Florida

Mariana Chavez MacGregor, MD, MSC
Associate Professor
Health Services Research
Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Sergio A. Giralt, MD
Deputy Head Division of Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief, Hematology and Oncology
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center

Taimur Sher, MD
Professor of Medicine
Consultant Hematology and Medical Oncology
Co-Chair Institutional Review Board
Medical Director Mortality Improvement
Florida
“OVERCOMING NEW CHALLENGES IN THE ONCOLOGY PRACTICE”

SPEAKERS 2021

Saranya Chumsri, M.D.
Associate Professor of Medicine
Jacoby Center for Breast Health
Mayo Clinic Cancer Center
South Jacksonville, FL

Eneida R. Nemecek, MD, MS, MBA
Nancy Jaggar Blount Endowed
Professor of Pediatrics & Medical Oncology
Medical Director of Clinical Research
Knight Cancer Institute
Oregon Health & Science University
Portland, OR

Michael L. Nieder, MD
Professor of Oncologic Sciences,
University of South Florida Morsani College of Medicine
Medical Director, Blood and Marrow Transplant and
Cellular Immunotherapy, H. Lee Moffitt Cancer Center
Tampa, FL

Carlos J. Pérez-López, MD
Infectious Diseases
Program Director Infectious Diseases TCT Oncology
BMT and Cellular Therapy Hospital Auxilio Mutuo
Department of Internal Medicine Hospital Auxilio Mutuo
Associated Professor Universidad Central del Caribe
San Juan, PR

Crystal S. Denlinger, MD FACP
Chief, Gastrointestinal Medical Oncology
Deputy Director, Phase 1 Program
Director, Survivorship Program
Associate Professor, Department of Hematology/Oncology
Philadelphia, PA

Sophie M. Lanzkron, MD, MHS
Professor in Medicine,
Department of Medicine (Hematology) and Oncology
Johns Hopkins University,
Baltimore, MD
Farhad Ravandi-Kashani, MD  
Professor, Department of Leukemia,  
Division of Cancer Medicine,  
The University of Texas MD Anderson Cancer Center,  
Houston, TX

Luis E. Raez, MD, FACP, FCCP  
Chief Scientific Officer & Medical Director  
Memorial Cancer Institute  
Director, Thoracic Oncology Program  
Memorial Health Care System  
Pembroke Pines, FL

Harold J. Burstein, MD, PhD  
Medical Oncologist at Dana-Farber Cancer Institute  
Professor of Medicine at Harvard Medical School  
Boston, MA

Alison J. Moskowitz, MD  
Associate Attending Physician Lymphoma Service  
Hematologic Oncology Division  
Department of Medicine  
Memorial Hospital for Cancer & Allied Diseases  
New York, NY

Guillermo García-Manero, M.D.  
Professor, Department of Leukemia,  
Chief, Section of Myelodysplastic Syndromes  
Fellowship Program Director  
Division of Cancer Medicine,  
The University of Texas MD Anderson Cancer Center,  
Houston, TX

Jesús San-Miguel, MD, PhD  
Professor of Medicine-Hematology  
Director of Clinical and Translational Medicine  
University of Navarra  
Spain

“OVERCOMING NEW CHALLENGES IN THE ONCOLOGY PRACTICE”
Wendy Stock, MD, MA  
Professor of Leukemia  
University of Chicago Medicine  
Chicago, IL

Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSMR  
Co-Director, Cardiac Radiology Services,  
Department of Diagnostic Radiology,  
Division of Diagnostic Imaging,  
Associate Professor, Department of Cardiology,  
Division of Internal Medicine  
The University of Texas MD Anderson Cancer Center,  
Houston, TX

PAUL GRAHAM FISHER, MD, MHS  
Division of Child Neurology  
Department of Neurology and Neurological Sciences  
Stanford University Medical Center  
Palo Alto, CA

Melissa Alsina, MD  
Head, Myeloma BMT-CI Program  
H. Lee Moffitt Cancer Center  
Tampa, Florida

Shayma Master Kazmi, M.D., R. Ph.  
Director of Advanced Center of Thoracic Oncology  
Medical Oncologist and Hematologist  
New Jersey

Raja Mudad, MD  
Oncologist, Founding Partner  
Florida Precision Oncology  
Miami, Florida
FRIDAY PM
MARCH 12, 2021

5:00 PM
REGISTRATION
Virtual Exhibits Opening

5:30 – 8:00 PM
Welcome Remarks
Dr. Sixto Pérez, MD
President AHOMPR

6:45 pm

7:00 – 7:30 PM
PROMOTIONAL SPEAKER PROGRAM
Topic: “Treatment Options for the Management of Certain Patients with First Line Non-Small Cell Lung Cancer”
By: Raja Mudad, MD
Sponsored by: BMS
A Non-CME activity

7:30 – 8:00 PM
SCIENTIFIC PROGRAM
Moderator: Dr. Alexis Cruz
JENARO HADDOCK MEMORIAL LECTURE
Topic: “Update Treatment AML: Targeted Agents”
Dr. Farhad Ravandi
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

8:00 PM
OPENING ARTISTIC ACTIVITY
MANOLO MONGIL
REGISTRATION

VIRTUAL EXHIBITS OPENING

PROMOTIONAL SPEAKER PROGRAM
Topic: “Redefining Approaches in Early-Line Multiple Myeloma Treatment (FASPRO™)”
By: Melissa Alsina, MD
Sponsored by: Janssen
A Non-CME activity

SCIENTIFIC PROGRAM
Moderator: Dr. Alexis Cruz

9:00-9:15 AM
WELCOME REMARKS
DR. SIXTO PEREZ - President AHOMPR

9:30-10:00 AM
Topic: “Next Generation Sequencing for patients with GI Cancer”
Dr. John L. Marshall - Lombardi Comprehensive Cancer Center (Georgetown U.)

10:00-10:30 AM
Topic: “Immunotherapy in GI Cancer”
Dr. Crystal Denlinger - Fox Chase Cancer Center (Temple University)

10:30- 11:00 AM
DR. ENRIQUE VELEZ GARCIA MEMORIAL LECTURE
Topic: “Early-stage Breast Cancer in the COVID19 Era”
Dr. Harold Burstein
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

11:00 – 11:30AM
Topic:” Amyloidosis Review”
Dr. Taimur Sher - Mayo Clinic (Jacksonville, Florida)

11:30 – 12:30 PM
VIRTUAL EXHIBITS - BREAK

12:30-1:00PM
Topic: “Relapsed/Refractory Hodgkin Lymphoma”
Dr. Alison J. Moskowitz - Memorial Sloan Kettering Cancer Center (NYC)

1:00-1:30PM
Topic: “New Options in Treatment for HER2+ Breast Cancer”
Dr. Mariana Chavez Mac Gregor - MD Anderson Cancer Center (Houston, TX)
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30-2:00PM</td>
<td><strong>Immunotherapy in Breast Cancer</strong></td>
<td>Dr. Saranya Chumski - Mayo Clinic (Jacksonville, Florida)</td>
</tr>
<tr>
<td>2:00 – 2:30 PM</td>
<td><strong>VIRTUAL EXHIBITS - BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td>Hematology-Oncology Fellows Cases Presentation</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Virtual Pediatric Oncology Section</strong></td>
<td></td>
</tr>
<tr>
<td>9:00 – 9:30 AM</td>
<td><strong>ALL in AYA Population</strong></td>
<td>Dr. Wendy Stock - University of Chicago Medicine (Chicago, IL)</td>
</tr>
<tr>
<td>9:30- 10:00 AM</td>
<td><strong>Aplastic Anemia and BM Failure Syndromes</strong></td>
<td>Dr. Michael Nieder - Moffitt Cancer Center (Tampa, FL)</td>
</tr>
<tr>
<td>10:00- 10:30 AM</td>
<td><strong>5 Brain Tumors in Children and Young Adults that Every Oncologist Should Know</strong></td>
<td>Dr. Paul Graham Fisher - Stanford University (Palo Alto, CA)</td>
</tr>
<tr>
<td>5:00pm</td>
<td><strong>Closing Artistic Activity</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Show: Hermes Croatto</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Raffle for Members Physicians ANOMPR</td>
<td></td>
</tr>
</tbody>
</table>

**SUNDAY MARCH 14, 2021**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM</td>
<td><strong>REGISTRATION</strong></td>
</tr>
<tr>
<td>8:00 AM</td>
<td><strong>VIRTUAL EXHIBITS OPENING</strong></td>
</tr>
<tr>
<td>8:30-9:00 AM</td>
<td><strong>PROMOTIONAL SPEAKER PROGRAM</strong></td>
</tr>
<tr>
<td></td>
<td>Topic: “An Individualized Approach: A CDK 4 &amp; 6 Inhibitor for Women with Reduced Survival in HR+, HER2- MBC”</td>
</tr>
<tr>
<td></td>
<td>Sponsored by: LILLY</td>
</tr>
<tr>
<td></td>
<td>A Non-CME activity</td>
</tr>
<tr>
<td>Time</td>
<td>Topic</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>9:15-9:45 AM</td>
<td><strong>Topic:</strong> “Immunotherapy in Non-Metastatic Lung Cancer”</td>
</tr>
<tr>
<td>9:45-10:15 AM</td>
<td><strong>Topic:</strong> “Mutation-Guided Therapy of Metastatic Lung Cancer: Current, New and Future Targets”</td>
</tr>
<tr>
<td>10:15-10:45 AM</td>
<td><strong>DR. ENRIQUE PÉREZ SANTIAGO MEMORIAL LECTURE</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45-11:15 AM</td>
<td><strong>Topic:</strong> “Updates in Smoldering MM”</td>
</tr>
<tr>
<td>12:30-1:00 PM</td>
<td><strong>Topic:</strong> “CART: Basic concepts for the Community Oncologist”</td>
</tr>
<tr>
<td>1:30-2:00PM</td>
<td><strong>Topic:</strong> “Cancer Patient Management during the COVID-19 Pandemic”</td>
</tr>
<tr>
<td>2:00- 2:30PM</td>
<td><strong>Topic:</strong> “Cardio-Oncology Overview: Basic concepts for the Oncology specialist”</td>
</tr>
<tr>
<td>2:30 PM</td>
<td><strong>VIRTUAL EXHIBITS - BREAK</strong></td>
</tr>
<tr>
<td></td>
<td><strong>VIRTUAL EXHIBITS - BREAK</strong></td>
</tr>
<tr>
<td>9:00 - 9:30AM</td>
<td><strong>Topic:</strong> “Pediatric Soft Tissue and Bone Sarcomas”</td>
</tr>
<tr>
<td>9:30 -10:00AM</td>
<td><strong>Topic:</strong> “Disease Modifying Therapy in Sickle Cell Disease”</td>
</tr>
<tr>
<td>10:00 - 10:30AM</td>
<td><strong>Topic:</strong> “Pediatric BMT Review”</td>
</tr>
<tr>
<td>11:15 -12:30PM</td>
<td><strong>VIRTUAL EXHIBITS - BREAK</strong></td>
</tr>
</tbody>
</table>
# CONFERENCE REGISTRATION FORM

ALL INFORMATION STATED ABOVE WILL REMAIN CONFIDENTIAL TO AHOMPR

PLEASE TYPE OR PRINT

Name: ____________________________ Medical License #: ____________________________

Last Name Initial

Medical Specialty: ____________________________

Mailing Address: ____________________________

Street Number Dept./Suite ____________________________

City State Zip Code ____________________________

Office: ____________________________ Cell: ____________________________ Fax: ____________________________

Home: ____________________________ E-mail: ____________________________

## REGISTRATION RATES

<table>
<thead>
<tr>
<th>Registration</th>
<th>Cash / Check</th>
<th>Credit Card</th>
</tr>
</thead>
<tbody>
<tr>
<td>AHOMPR Members*</td>
<td>FREE</td>
<td>FREE</td>
</tr>
<tr>
<td>Fellows**</td>
<td>FREE</td>
<td>FREE</td>
</tr>
<tr>
<td>Non-Member Physicians***</td>
<td>$260.00</td>
<td>$270.00</td>
</tr>
</tbody>
</table>

**These fees allows the registrant to participate in the conferences.**

Payment Type: ___ Check (Please Enclose) ___ Visa ___ Master Card (Sorry. No AMEX)

Cardholder’s Name: ____________________________ Signature: ____________________________

Card Number: ____________________________ Exp. Date: ____________________________ Security Code#: ____________________________

Make all checks payable to:

Asociación de Hematología y Oncología Médica de PR
PO Box 801195
Coto Laurel PR 00780-1195

For more information:

Germaine Quiñones
Meeting Coordinator
Tel: 787-608-1477
Fax: 787-841-6886
e-Mail: ahomprgq@gmail.com

Cancellation Policy: In case of no show, one night stay penalty will be applied. Cancellations will be accepted with no penalty up to 72 hours prior to arrival. Penalties will be your responsibility.